GC
ADMS

Globeflex Capital’s Adamas Pharmaceuticals ADMS Stock Holding History

Globeflex Capital’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-21,598
Closed -$612K – 511
2015
Q4 		$612K Buy
+21,598
New +$364K 0.16% 211

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Globeflex Capital's ADMS Position: Q1 2016 in Review

Globeflex Capital sold out of Adamas Pharmaceuticals (ADMS) in Q1 2016, closing a stake of 21,598 shares — an estimated $612K sold.

Globeflex Capital first reported a position in ADMS in Q4 2015 and held it in 1 quarter. The position peaked at $612K in Q4 2015. 84 funds tracked by Wall St. Rank hold ADMS as of Q1 2016.

  • Globeflex Capital reported no remaining Adamas Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Globeflex Capital sold 21,598 Adamas Pharmaceuticals shares in Q1 2016, an estimated $612K.
  • Globeflex Capital first reported a position in Adamas Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Globeflex Capital's Adamas Pharmaceuticals position peaked at $612K in Q4 2015.
  • 84 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2016.

Based on Globeflex Capital's 13F filing for Q1 2016, filed 3 May 2016.